New York, New York-- (Newsfile Corp. - January 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The Biden administration’s selection of 15 new drugs for price negotiations is reigniting the call from opponents to amend how drugs can be selected for the Medicare program.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

Welcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the ...

Eli Lilly's LLY short percent of float has risen 5.88% since its last report. The company recently reported that it has 6.10 million shares sold short, which is 0.72% of all regular shares that are ...

Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995 ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...